Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023

SELL
$1.85 - $2.6 $1,150 - $1,617
-622 Reduced 95.69%
28 $0
Q3 2022

Nov 03, 2022

BUY
$2.29 - $4.08 $1,488 - $2,652
650 New
650 $1,000
Q1 2022

May 16, 2022

SELL
$3.45 - $8.77 $8,017 - $20,381
-2,324 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$8.01 - $12.84 $330,524 - $529,829
-41,264 Reduced 94.67%
2,324 $19,000
Q3 2021

Nov 09, 2021

SELL
$11.94 - $16.09 $236,423 - $318,598
-19,801 Reduced 31.24%
43,588 $549,000
Q2 2021

Aug 13, 2021

BUY
$14.36 - $20.93 $576,884 - $840,820
40,173 Added 173.04%
63,389 $980,000
Q1 2021

May 13, 2021

BUY
$18.19 - $33.25 $339,934 - $621,376
18,688 Added 412.72%
23,216 $469,000
Q4 2020

Feb 11, 2021

BUY
$15.87 - $31.64 $64,162 - $127,920
4,043 Added 833.61%
4,528 $123,000
Q3 2020

Nov 12, 2020

BUY
$15.7 - $20.84 $7,614 - $10,107
485 New
485 $9,000
Q1 2020

May 13, 2020

SELL
$7.81 - $18.82 $554 - $1,336
-71 Closed
0 $0
Q4 2019

Feb 10, 2020

SELL
$9.73 - $19.31 $2,821 - $5,599
-290 Reduced 80.33%
71 $1,000
Q3 2019

Nov 14, 2019

BUY
$10.15 - $16.89 $2,639 - $4,391
260 Added 257.43%
361 $4,000
Q2 2019

Aug 14, 2019

SELL
$14.6 - $20.6 $16,512 - $23,298
-1,131 Reduced 91.8%
101 $2,000
Q1 2019

May 15, 2019

BUY
$15.53 - $19.75 $17,781 - $22,613
1,145 Added 1316.09%
1,232 $23,000
Q4 2018

Feb 14, 2019

BUY
$15.58 - $28.41 $15 - $28
1 Added 1.16%
87 $1,000
Q3 2018

Nov 14, 2018

SELL
$25.99 - $30.6 $123,712 - $145,656
-4,760 Reduced 98.23%
86 $2,000
Q2 2018

Aug 14, 2018

SELL
$27.78 - $38.53 $166 - $231
-6 Reduced 0.12%
4,846 $137,000
Q1 2018

May 15, 2018

BUY
$27.78 - $35.19 $1,444 - $1,829
52 Added 1.08%
4,852 $152,000
Q4 2017

Feb 14, 2018

SELL
$23.33 - $35.01 $240,298 - $360,603
-10,300 Reduced 68.21%
4,800 $140,000
Q3 2017

Nov 14, 2017

BUY
$21.65 - $32.18 $326,915 - $485,918
15,100
15,100 $430,000

Others Institutions Holding CLLS

About Cellectis S.A.


  • Ticker CLLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,510,800
  • Market Cap $71M
  • Description
  • Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...
More about CLLS
Track This Portfolio

Track Barclays PLC Portfolio

Follow Barclays PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.